Australian Court Restrains Apotex Challenge To Cipla-Meda’s Dymista
Apotex’s plans to launch a nasal spray formulation that competes with Cipla-Meda’s Dymista has been blocked by the Federal Court of Australia, at least for now. Apotex has challenged the validity of certain claims of the patent pertaining to Dymista.
You may also be interested in...
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.